



Widespread acneiform eruption in a young child secondary to histone deacetylase inhibitor

We report the case of a 2-year-old Caucasian boy with a diagnosis of a relapsed malignant rhabdoid tumour who had been recently commenced on panobinostat, a histone deacetylase inhibitor that is currently used in clinical trials for the treatment of various haematological conditions. The patient presented with an asymptomatic widespread acneiform eruption primarily affecting the face, with some involvement of the arms, trunks, buttocks and legs. This eruption developed within three weeks of commencing panobinostat and responded to treatment with topical erythromycin. This is a rarely reported incidence of an acneiform eruption associated with a histone deacetylase inhibitor in a young child, and the first report of a drug eruption secondary to panobinostat.